Analysis on the Infection Risk, Prognosis, and Drug Sensitivity of Klebsiella Pneumoniae.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04337840

Enrollment

200

Registered

2020-04-08

Start date

2020-05-05

Completion date

2022-03-31

Last updated

2020-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Klebsiella Pneumoniae Sepsis

Keywords

risk factors ,outcomes,Drug Susceptibility,Klebsiella pneumoniae

Brief summary

Nosocomial infections are increasing rapidly both internationally and domestically, especially carbapenem-resistant Klebsiella pneumoniae infections. However, there were still lack of evidence about the risk and prognosis in Taiwan. The choice of drug and related sensitivity test was also limited. We would analyze the infection risk, prognosis, and drug sensitivity of Klebsiella pneumoniae and focus on strategy to manage carbapenem-resistant Klebsiella pneumoniae infections.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to 100 Years

Healthy volunteers

Inclusion criteria

All adult patients (≥18 years) with K. pneumoniae bloodstream infection were included. Patients were excluded if there was other recognized bacteremia within two weeks before or after the first episode of K. pneumoniae bloodstream infection.

Design outcomes

Primary

Measure	Time frame
All-cause 28-day mortality	2017-2019

Countries

Taiwan

Contacts

Primary ContactJen-Yu Hsu

b94401012@g.ntu.edu.tw0922868936

Outcome results